Predicting risk of airflow obstruction in primary care: Validation of the lung function questionnaire (LFQ)  by Hanania, Nicola A. et al.
Respiratory Medicine (2010) 104, 1160e1170ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedPredicting risk of airflow obstruction in primary
care: Validation of the lung function
questionnaire (LFQ)Nicola A. Hanania a,*, David M. Mannino b, Barbara P. Yawn c,
Douglas W. Mapel d, Fernando J. Martinez e, James F. Donohue f,
Mark Kosinski g, Regina Rendas-Baum g, Matthew Mintz h, Steven Samuels i,
Priti Jhingran j, Anand A. Dalal ja Pulmonary and Critical Care Medicine, Baylor College of Medicine, 1504 Taub Loop, Houston, TX 77030, Texas, USA
b University of Kentucky School of Medicine, Lexington, KY, USA
c Olmsted Medical Center, Department of Research, Rochester, MN, USA
d Lovelace Clinic Foundation, Albuquerque, NM, USA
e University of Michigan Health System, Ann Arbor, MI, USA
f University of North Carolina School of Medicine, Chapel Hill, NC, USA
g QualityMetric, Inc., Lincoln, RI, USA
h George Washington University School of Medicine, Washington, DC, USA
i Indiana Internal Medicine Consultants, Greenwood, IN, USA
j GlaxoSmithKline, Research Triangle Park, NC, USA
Received 21 December 2009; accepted 10 February 2010
Available online 11 March 2010KEYWORDS
Case finding tool;
Spirometry;
Chronic obstructive
pulmonary disease;
Health survey;
Risk of obstruction;
Screening tool* Corresponding author. Tel.: þ1 71
E-mail address: hanania@bcm.tmc
0954-6111/$ - see front matter ª 201
doi:10.1016/j.rmed.2010.02.009Summary
The Lung Function Questionnaire (LFQ) is being developed as a case finding tool to identify
patients who are appropriate for spirometry testing to confirm the diagnosis of chronic
obstructive pulmonary disease (COPD). The cross-sectional study reported herein was con-
ducted to validate the LFQ, to identify item-response scales associated with the best accuracy,
and to determine the impact on accuracy of the addition of another item on activity limitations
(AL). Patients  40 years old seen at 2 primary care offices completed the LFQ, a demographic
questionnaire followed by spirometry. Of the 837 evaluable patients, 18.6% had airflow
obstruction (forced expiratory volume in 1 s/forced vital capacity [FEV1/FVC] < 0.70). The 5
items (age, wheeze, dyspnea, smoking, and cough) previously identified in initial LFQ develop-
ment predicted airflow obstruction and showed good evidence of screening accuracy.
Screening accuracy was significantly better with 5-point ordinal item-response scales (78%)38733454; fax: þ1 7138733346.
.edu (N.A. Hanania).
0 Elsevier Ltd. All rights reserved.
Validation of the LFQ 1161than binary (yes/no) item-response scales (74%)(p < 0.05). Screening accuracy was good
regardless of whether airflow obstruction was defined as FEV1/FVC < 0.70 or FEV1/
FVC < 0.70 and FEV1 < 80% of predicted. Based on 18 was selected to suggest presence of
airflow obstruction with area under the receiver operating characteristic curve 0.652; sensi-
tivity 82.6%; specificity 47.8%; 54.3% correctly classified. While the specificity of LFQ is low,
its high sensitivity suggests that it can serve to identify patients who should be further assessed
using spirometry. Our results confirm the screening accuracy of the LFQ, a simple and effective
tool to facilitate early recognition and diagnosis of COPD.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
Chronic obstructive pulmonary disease (COPD) is a global
health problem that by 2020 is projected to rank fifth in
burden of disease worldwide.1 Although damage to lung
tissue in COPD appears to be irreversible, evidence suggests
the course of COPD can be altered through measures such as
smoking cessation, pulmonary rehabilitation, oxygen, and
use of pharmacotherapy.2e6 Demonstrations of intervention-
associated reductions in symptoms and frequency of exac-
erbations and improvement in exercise capacity in studies
such as the TORCH trial7 and other large, randomized trials8,9
have shifted the focus of COPD management from symp-
tomatic and supportive care to disease-modifying interven-
tions.3,4 In this new paradigm for managing COPD, early
identification of the disease is regarded as integral to opti-
mizing outcomes.5 To this end, the multinational ECLIPSE
trial (Evaluation of COPD Longitudinally to Identify Predic-
tive surrogate Endpoints) is designed to identify parameters
andbiomarkers that predict progression inCOPDand that can
ultimately be used to optimize treatment.10e12 Likewise,
multinational trials such as UPLIFT (Understanding the
Potential Long-Term Impacts on Function with Tiotropium)
are helping to increase understanding of the natural history
of COPD ina global population and to shed light onpotentially
disease-modifying approaches to therapy.13
COPD remains undiagnosed in almost 50%of thosepatients
who suffer from this disease.14 Early recognition of COPD can
be challenging because patients and health care profes-
sionals often fail to recognize early manifestations of the
disease.2 According to both the Global Initiative for Chronic
Obstructive Lung Disease (GOLD) guidelines1 and the Amer-
ican Thoracic Society/European Respiratory Society (ATS/
ERS) Standards for the Diagnosis andManagement of Patients
with COPD,15 spirometry is crucial to confirm the diagnosis of
COPD. The ATS/ERS Standards for the Diagnosis and
Management of Patients with COPD state that case finding is
a simple and effective means of enhancing the diagnosis of
COPD in primary care and recommend spirometry by primary
care providers to detect airway obstruction and facilitate
smoking cessation.15 However, primary care health profes-
sionals often lack spirometry equipment and have no prac-
tical tools to help identify COPD at an early stage when
symptoms and activity restrictions may be subtle.2
The Lung Function Questionnaire (LFQ) is a simple, brief,
self-administered instrument, being developed to address
the need for a screening tool to identify patients appro-
priate for COPD spirometry-confirmed diagnostic evalua-
tion. The questionnaire16 is based on data obtained from
a sample of adults who self-reported chronic bronchitisduring the Third National Health and Nutrition Examination
Survey (NHANES III). Items from the NHANES III that could
discriminate between patients with and without
spirometry-based airflow obstruction, the primary mani-
festation of COPD, were identified for possible inclusion in
the LFQ. Item reduction phases of development resulted in
a set of five questions that had very good screening accu-
racy, specificity, and sensitivity. The final step in the
development phase is the need to validate the LFQ and to
identify item-response scales (yes/no versus five-point
scale) associated with the greatest accuracy. Since
activity limitation is believed to be an important outcome
of COPD, this study also assessed the impact of adding an
activity limitations (AL) item to the LFQ screening accu-
racy. Because primary care physicians are thought to
provide care for the majority of patients with early or mild
COPD and are crucial in efforts to diagnose COPD earlier,2
this study was conducted in two primary care practices.
Methods
Design and sample
This cross-sectional study was conducted from March to May
2008 in two family physician group officesdone in a rural
Kentucky (Hazard) and one in a large Kentucky metropolitan
area (Lexington). The University of Kentucky institutional
review board (IRB) approved the protocol for both study sites.
Men andwomen 40 years and older visiting the practices were
eligible. No other inclusion or exclusion criteria were applied.
Procedures
Patients who agreed to participate in the study and who
provided informed consent completed the LFQ and
a demographic questionnaire in the waiting room. The LFQ
comprised an age item, a smoking item, 3 symptom items
(cough, dyspnea, wheeze), and, for some participants, an
item on AL (Table 1). Symptom items were administered
with both a binary response scale (yes or no) and an ordinal
response scale (Table 1). After patients completed the
questionnaires, pre-bronchodilator (pre-BD) spirometry was
performed using EasyOne spirometers.
Data analysis
Data analyses were conducted in 3 phases. In the first
phase, the degree to which the AL item could significantly
predict airflow obstruction status was determined. Chi-
Table 1 Items used in the LFQ scale analyses.
Factor Question Response choices
Age Age 50 or older (dichotomized answers to question above) Yes/No
What is your age range? 40e50, 50e60, 60e70, 70 þ years
Cough Do you frequently cough mucus? Yes/No
How often do you cough mucus? Very often, often, sometimes, rarely, never
Wheeze Does your chest often sound noisy (wheezy, whistling)
when you breathe?
Yes/No
How often does your chest sound noisy (wheezy, whistling)
when you breathe?
Very often, often, sometimes, rarely, never
Dyspnea Do you experience shortness of breath upon physical exertion? Yes/No
How often do you experience shortness of breath
upon physical exertion
Very often, often, sometimes, rarely, never
Smoking Smoked at least 20 years (dichotomized answers to question above) Yes/No
How many years did you or have you smoked? Never, 10 or less, 11e20, 21e30,
31e40, 41e50, 50þ years
AL Feels limited often or very often Yes/No
How often limited in daily activities by your breathing problems? Very often, often, sometimes, rarely, never
1162 N.A. Hanania et al.square tests of statistical independence were used to
determine whether obstructed respondents and non-
obstructed respondents differed significantly on the AL
item and each of the remaining LFQ items. Airflow
obstruction was defined as a ratio of the forced expiratory
volume in 1 s (FEV1) to the forced vital capacity
(FVC) < 0.70 (FEV1/FVC < 0.70) (pre-BD). Investigators
rated spirometry quality as Grade 1 (reliable and repro-
ducible), Grade 2 (reliable but not reproducible), or Grade
3 (neither reliable nor reproducible). Only spirometries of
Grades 1 and 2 were included in the analyses. Very few
spirometries were Grade 3.
In the second phase of analysis, alternative LFQ scales
comprising various combinations of the items with binary
and ordinal response scales were compared. Binary
multiple logistic regression was used to compare the scales
in terms of sensitivity, specificity, and the area under the
receiver operating characteristic (ROC) curve (AUC). The
dependent variable was airflow obstruction (1 Z yes,
0 Z no). The estimated odds ratios were examined to
confirm the expected relationship between each LFQ item
and airflow obstruction (i.e., whether greater symptom
severity, older age, and more years smoked were associ-
ated with greater risk of obstruction) and to study potential
changes to each of the original item scales (caused by
possibly redundant response choices). Wald chi-square
tests were used to establish statistical significance. In
addition to the AUC obtained using the full set of LFQ items
as predictors of obstruction, a second scale-specific AUC
value was derived from a binary logistic regression model in
which the scale’s summed score was the only independent
variable predicting obstruction. Tests of statistical signifi-
cance for the difference between the AUCs of 2 scales were
conducted using the method of Delong and Delong.17
As part of the second phase of analyses, additional
sensitivity analyses were conducted to evaluate the accu-
racy of the LFQ using FEV1% predicted with the fixed ratio
(FEV1/FVC < 70%). Airway obstruction was defined (regard-
less of age) as having both FEV1/FVC < 70% and % predicted
FEV1 < 80% to resemble more closely GOLD stage 2 severity.In the third phase of analyses, the best-performing scale
was chosen based on measures of predictive accuracy (AUC,
sensitivity, specificity, positive predictive value [PPV],
negative predictive value [NPV], and percentage of
correctly classified observations) as well as clinician input
keeping in mind the intended purpose of the tool. For these
analyses, a scale was obtained by simple summation of the
LFQ items. Binary (0/1) cumulative summed score indica-
tors were created for each value of the scale. Each of these
variables was subsequently used as the predictor of airway
obstruction using binary logistic regression. The predictor in
the model with the highest AUC reflected the minimum
score of the LFQ that most accurately predicted airway
obstruction.
Discriminant validity was assessed via the method of
known-groups validity18 and using spirometry-defined
severity stages among those who were obstructed. These
analyses determined whether LFQ scores discriminated
among patients of differing levels of severity. LFQ scores
were also examined across levels of general health (using
SF-1). One-way analysis of variance (ANOVA) was used to
compare the performance of alternative LFQ scales.
Upon selection of the items and response options, the
resulting questionnaire was tested via one-on-one cognitive
interviews in 15 patients with confirmed chronic bronchitis,
emphysema, or COPD. The interviews provided patient
input and feedback on the readability of the instructions,
questions, response options, and scoring. A key objective of
these qualitative interviews was to explore the format and
content of the AL question in an effort to define the
concept of activity limitation more fully.
Results
Sample
937 patients participated in this study. Of these 937, 855
patients provided evaluable data for the main analysis
variables. Of these 855 patients, 18 were excluded based
Table 2 Demographics of study population.
FEV1/FVC  70% (n Z 681) FEV1/FVC < 70% (n Z 156) All (N Z 837)
% Respondents
Age
40e49 38.2 21.8 35.1
50e59 32.3 29.5 31.8
60e69 19.4 27.6 20.9
70þ 10.0 20.5 11.9
NA 0.1 0.6 0.2
Sex
Male 36.1 46.8 38.1
Female 63.7 52.6 61.6
NA 0.1 0.6 0.2
Race
White 85.9 91.0 86.9
Black 10.9 7.1 10.2
Asian 1.9 0.6 1.7
American Indian/Alaskan native 0.7 0.0 0.6
Other 0.3 0.6 0.4
NA 0.3 0.6 0.4
Education
No school 0.3 1.3 0.5
1e8 8.7 21.8 11.1
9e12 13.1 20.5 14.5
12 or General educational development 31.6 23.7 30.1
13e15 24.7 16.7 23.2
16þ Years 20.7 13.5 19.4
NA 1.0 2.6 1.3
Employment
Employed 41.4 19.2 37.3
Self-employed 4.3 4.5 4.3
Disabled 27.9 45.5 31.2
Out of work >1 Year 2.2 0.6 1.9
Out of work <1 Year 1.2 1.3 1.2
Homemaker 6.9 6.4 6.8
Student 0.7 0.6 0.7
Retired 15.0 19.9 15.9
NA 0.4 1.9 0.7
Validation of the LFQ 1163on inconsistent responses on smoke-related questions to
yield a total sample of 837 for all items. The AL question
was given to 304 patients.
Demographics of the sample as a whole and the
subgroups with and without airflow obstruction are shown
in Table 2. FEV1/FVC ratio was <0.70 in 156 respondents for
a prevalence of airflow obstruction of 18.6%.
Impact of the AL item on accuracy
Table 3 shows the distribution of responses on LFQ items for
the subsample (n Z 304) that completed the AL item. The
extent to which the respondent reported being limited in
daily activities did not predict the presence of airflow
obstruction (P Z 0.2003) (Table 3). The majority of
respondents indicated presence of some level of dyspnea
but also reported not being limited in activities they per-
formed. This pattern of results suggests that the wording ofthe AL question might not have been sufficiently explicit in
eliciting appropriate responses from patients. This possi-
bility was explored in subsequent patient interviews,
results of which are described below. Given that the AL
item was not significantly associated with obstruction
status, this item was not considered in further analyses.
Comparison of scoring formats
Results of a comparison of the accuracy of the LFQ with all
binary item-response scales versus the LFQ with all ordinal
item-response scales suggest that the latter was more accu-
rate as measured by AUC (binary AUC Z 0.739 [95% confi-
dence interval (CI) Z 0.695e0.783]; ordinal AUC Z 0.777
[95%CIZ 0.736e0.818];PZ 0.0049). This result supports the
use of ordinal response options or LFQ items.
The item on number of years smoked was collapsed from
7 response categories to 5 response categories based on
Table 3 Responses on LFQ items for the subsample completing the AL item.
Factor FEV1/FVC  70%
(n Z 258)
FEV1/FVC < 70%
(n Z 46)
All
(N Z 304)
% respondents
How often activities limited?
P Z 0.2003
Never 47.3 32.6 45.1
Rarely 24.8 23.9 24.7
Sometimes 17.4 23.9 18.4
Often 5.8 8.7 6.3
Very often 4.7 10.9 5.6
Age
P Z 0.401
40e49 36.4 23.9 34.5
50e59 34.5 41.3 35.5
60e69 20.2 26.1 21.1
70þ 8.9 8.7 8.9
Years smoked?
P Z 0.0001
Never smoked 50.8 21.7 46.4
10 Years 13.6 8.7 12.8
11e20 Years 12.8 13.0 12.8
21e30 Years 11.6 23.9 13.5
31e40 Years 7.8 19.6 9.5
41e50 Years 3.1 8.7 3.9
>50 Years 0.4 4.3 1.0
How often cough?
P Z 0.0105
Never 27.1 13.0 25.0
Rarely 36.8 23.9 34.9
Sometimes 23.3 43.5 26.3
Often 8.1 15.2 9.2
Very often 4.7 4.3 4.6
How often short of breath? (dyspnea)
P Z 0.0650
Never 17.1 4.3 15.1
Rarely 23.3 23.9 23.4
Sometimes 29.1 32.6 29.6
Often 15.1 28.3 17.1
Very often 15.5 10.9 14.8
How often noisy breathing? (wheeze)
P Z 0.0002
Never 39.5 15.2 35.9
Rarely 33.7 26.1 32.6
Sometimes 16.3 43.5 20.4
Often 6.6 8.7 6.9
Very often 3.9 6.5 4.3
Total (obstructed: 46/304 Z 15.1%) 100.0 100.0 100.0
P-values are derived from chi-square significance tests of difference in the distribution of symptom categories across obstructed and
non-obstructed groups.
1164 N.A. Hanania et al.odds ratios and distribution of responses as well as high
standard errors in the extreme categories (31e40 years,
41e50 years, and more than 50 years). The recoded smoke
variable consisted of a 5-point ordinal scale including the
categories of never, 10 or fewer years, 11e20 years, 21e30
years, and 31þ years. The recoded smoke variable was
evaluated further in patient interviews. Table 4 shows the
results of multivariate logistic regression analyses under-
taken between the binary scale and the ordinal scale after
recoding smoke into 5 categories. Given these results, data
obtained from other models (not shown), and the input of
LFQ Working Group, ordinal item-response scales including
the 5-category scale for the item for the number of years
smoked were chosen for further evaluation. Although cough
and dyspnea did not achieve statistical significance in both
response formats, they were included in the questionnaire
based on clinical relevance (face validity).
In the sensitivity analysis that defined airflow obstruc-
tion as FEV1/FVC < 70% and FEV1 < 80% of predicted, 19respondents who had previously been classified as
obstructed were reclassified for a change in the prevalence
from 18.6% to 16.4%. With this definition of obstruction I
compared with the fixed ratio of FEV1/FVC, a slightly higher
AUC was observed (0.765 versus 0.743 for the summed score
scale) (Table 5). However, the relationship between indi-
vidual items and airflow obstruction status was generally
similar between the approaches (Table 5).Predictive accuracy and classification threshold of
the LFQ
Table 6 shows several measures of accuracy for various
cutpoints of the LFQ scale that included ordinal item-
response scales with the 5-category scale for the item for
the number of years smoked. A score of 18, which yielded
an AUC of 0.652, sensitivity of 82.6%, and specificity of
47.8%, was selected as appropriate cut point for the LFQ as
Table 4 Results of multiple logistic regression analyses for binary item-response scales versus ordinal item-response scales.
Binary item-response scales Ordinal item-response scales
Odds ratio (95% CI) Response choices Odds ratio (95% CI)
Agea 2.146 (1.39e3.32) 70þ y 4.733 (0.53e8.85)
60e70 y 3.219 (1.82e5.70)
50e60 y 1.571 (0.93e2.65)
Smokea 3.232 (2.21e4.74) 31þ y 3.601 (2.04e6.35)
21e30 y 4.260 (2.40e7.57)
11e20 y 1.990 (1.03e3.85)
10 y 1.253 (0.58e2.70)
Cough 1.959 (1.26e3.04) Very often 1.159 (0.37e3.65)
Often 0.999 (0.40e2.51)
Sometimes 0.903 (0.42e1.96)
Rarely 0.572 (0.27e1.23)
Dyspnea 0.872 (0.54e1.40) Very often 1.359 (0.48e3.84)
Often 1.653 (0.61e4.50)
Sometimes 1.445 (0.55e3.78)
Rarely 1.887 (0.71e5.04)
Wheezea 1.755 (1.12e2.76) Very often 3.364 (1.06e10.71)
Often 4.888 (1.97e12.15)
Sometimes 2.619 (1.23e5.58)
Rarely 1.688 (0.84e3.41)
Model AUC (95% CI) 0.739 (0.695e0.783) na 0.777 (0.736e0.818)
Sum score AUC (95% CI) 0.718 (0.673e0.763) na 0.742 (0.699e0.786)
For binary (yes/no) symptom items, the reference category is ‘no’ (i.e., symptom absent). For dichotomized age and smoke, <50 and
<20 were the reference categories, respectively. For ordinal (5-point scale) items, the first category was taken as the reference (‘never’
for symptom and smoke items, 40e50 for age).
Model AUC refers to the area under curve for a model in which the LFQ items are the 5 predictors of obstruction while the sum score AUC
indicates the AUC for a model in which the sum of the 5 items forms a single predictor of obstruction.
For yes/no option, only dyspnea did not reach statistical significance.
a Age, smoking and wheeze P < 0.05 and therefore statistically significant for 5-point scale.
Validation of the LFQ 1165a case finding tool. Using an LFQ score of 18 or lower as
consistent with failed screening, 54.3% of the sample were
correctly classified as either obstructed or not (Table 6). A
negative predictive value of 92% shows that the instrument
was extremely accurate in not missing many cases with
potential COPD, a vital characteristic for a case finding
tool. LFQ showed good discriminant validity across
spirometry-defined severity groups as well as general
health. LFQ is scored such that lower scores indicate higher
risk of obstruction. In addition, LFQ scores discriminated
among patients of differing levels of severity as defined in
on the GOLD guidelines although FEV1 measurement was
based on pre-bronchodilator values (Table 7).
Results of cognitive debriefing interviews
Overall, patients preferred the 5-point scoring to the yes/
no responses. Some changes were made to the instructions
at the beginning to clarify the intent of the questionnaire
(Fig. 1) as well as instructions at the end. Other major
changes included replacement of the word ‘‘exertion’’ by
the word ‘‘activity’’ in question 3; inclusion of the term
‘‘rattling’’ in question 2; and simplification of the smoking
and age questions. This phase ensured that readability and
understandability of patients with the LFQ were good. Two
versions of the AL item were explored: 1) How often are you
limited in your daily activities by your breathing problems?;2) Thinking about your health BEFORE you had breathing
problems, how often are you limited in your daily activities
(such as household chores, social activities, going to work)
by your breathing problems? Patients could not agree on 1
of these items, and items could not be sufficiently refined
to obtain saturation. Therefore, this question was not
included in the LFQ but will continue to be explored in
future studies.
Discussion
The diagnosis of COPD requires objective evidence of
airflow limitation in patients with risk factors such as
smoking and/or symptoms of chronic sputum production,
wheezing, and dyspnea.1 However, spirometry has not been
shown to be a practical screening tool in every patient with
smoking history. Spirometry is also very rarely utilized in
primary care for identifying risk of airflow obstruction
because of its lack of practicality and some practitioners’
lack of awareness of its application. In addition, health care
professionals and patients often miss the subtle early-stage
symptoms leaving COPD to be underdiagnosed.19e21 Simple,
valid, sensitive yet specific case finding tools are needed to
identify COPD when the attempts at disease modification
remain feasible. In this study, the brief, self-administered
LFQ containing items on age, smoking, cough, dyspnea,
and wheeze predicted airflow obstruction and showed
Table 5 Results of multiple logistic regression analyses for the criterion measure of airflow obstruction defined as FEV1/
FVC < 0.7 versus FEV1/FVC < 0.7 and FEV1 < 80%.
Factor Standard definition (Fixed ratio < 0.7) Modified definition
Odds ratio (95% CI) Odds ratio (95% CI)
Age
70þ y 4.733 (2.53e8.85) 4.700 (2.42e9.14)
60e70 y 3.219 (1.82e5.70) 3.054 (1.65e5.65)
50e60 y 1.571 (0.93e2.65) 1.729 (1.00e3.01)
Smoke
31þ y 3.601 (2.04e6.35) 4.575 (2.47e8.47)
21e30 y 4.260 (2.40e7.57) 4.828 (2.57e9.05)
11e20 y 1.990 (1.03e3.85) 2.215 (1.07e4.57)
10 y 1.253 (0.58e2.70) 1.404 (0.60e3.29)
Cough
Very often 1.159 (0.37e3.65) 0.950 (0.28e3.18)
Often 0.999 (0.40e2.51) 0.878 (0.33e2.36)
Sometimes 0.903 (0.42e1.96) 0.775 (0.33e1.81)
Rarely 0.572 (0.27e1.23) 0.522 (0.22e1.21)
Dyspnea
Very Often 1.359 (0.48e3.84) 1.457 (0.45e4.72)
Often 1.653 (0.61e4.50) 2.220 (0.71e6.90)
Sometimes 1.445 (0.55e3.78) 1.381 (0.45e4.20)
Rarely 1.887 (0.71e5.04) 2.191 (0.71e6.75)
Wheeze
Very often 3.364 (1.06e10.71) 4.783 (1.41e16.21)
Often 4.888 (1.97e12.15) 5.280 (1.97e14.15)
Sometimes 2.619 (1.23e5.58) 3.369 (1.46e7.77)
Rarely 1.688 (0.84e3.41) 1.718 (0.78e3.79)
AUC 0.776 0.794
Sum score AUC 0.743 0.765
Note: GOLD Stage II Definition of Airflow Obstruction is FEV1/FVC < 70% and FEV1 < 80% of predicted. Fixed ratio refers to FEV1/
FVC < 70% only. Applied only to patients with obstruction (by definition). Pre-BD spirometry used in this study.
Table 6 Performance of LFQ items in screening for airflow
obstruction: sensitivity and specificity.
Cut
point
Sensitivity Specificity PPV NPV %
Correct
AUC
8 5.2 98.8 50.0 82.1 81.4 0.520
9 8.4 98.5 56.5 82.5 81.8 0.535
10 13.5 97.1 51.2 83.1 81.6 0.553
11 21.3 94.3 45.8 84.0 80.7 0.578
12 32.9 91.8 47.7 85.7 80.8 0.623
13 43.9 87.9 45.3 87.3 79.8 0.659
14 53.5 82.9 41.7 88.7 77.5 0.682
15 61.9 74.1 35.3 89.5 71.9 0.680
16 71.0 66.5 32.5 90.9 67.3 0.687
17 76.8 56.9 28.9 91.5 60.6 0.668
18 82.6 47.8 26.5 92.3 54.3 0.652
19 88.4 36.8 24.2 93.3 46.3 0.626
20 93.5 26.6 22.5 94.8 39.0 0.601
21 95.5 18.8 21.1 94.8 33.1 0.572
22 98.1 11.6 20.2 96.3 27.7 0.548
23 98.7 5.6 19.2 95.0 22.9 0.521
24 99.4 1.9 18.8 92.9 20.0 0.506
1166 N.A. Hanania et al.strong evidence of screening accuracy in a primary care
population. The summed score of the LFQ scale containing
the age, smoking, cough, dyspnea, and wheeze items
ranged between 5 and 25 points. The LFQ is intended to
identify patients at risk for obstruction who are candidates
for further evaluation via spirometry to confirm diagnosis of
COPD wherever applicable. Cut point selection is typically
amenable to adaptation for specific purposes. An expert
panel of clinicians felt that a cut point with higher sensi-
tivity would be more appropriate (not missing many
‘‘cases’’) keeping in mind the high prevalence of undiag-
nosed COPD in primary care. Accordingly, a high NPV means
that of those who test negative for risk of COPD, the LFQ
correctly identifies 92% of patients who do not have COPD.
The LFQ therefore captures the majority of patients who
may have potential COPD. Underdiagnosis is a troublesome
problem in COPD and the focus for a screening test is
therefore upon not missing undiagnosed patients who may
progress onto a severe stage before being diagnosed.
Therefore, a cut point score of 18 was selected to identify
patients at risk of obstruction despite the fact that a score
of 16 yielded the highest AUC. This tool focuses on
capturing early COPD. Although it does not address other
respiratory conditions, it does facilitate patient-physician
Table 7 Known-groups discriminant validity of LFQ using gold stage, FEV1% predicted, general health, and FEV1/FVC fixed ratio.
GOLD stagea I mild (17) II moderate (76) III severe (44) IV Very severe (11) F-statistic
Mean (SD) LFQ score 16.76 (3.7) 15.01 (3.7) 13.25 (3.3) 11.55 (2.8) 7.12*
FEV1% predicted (n) 100% (132) 80 to <100% (327) 60 to <80% (256) <60% (122)
Mean (SD) LFQ score 19.13 (3.2) 18.60 (3.5) 16.65 (3.6) 13.43 (3.4) 79.18*
General health (n) Excellent/Very good (29) Good (52) Fair (46) Poor (19)
Mean (SD) LFQ score 17.69 (2.7) 14.00 (3.9) 14.17 (3.2) 11.32 (2.4) 68.23*
FEV1/FVC (n) 70% (681) <70% (156)
Mean (SD) LFQ score 17.97 (3.7) 14.54 (3.8) 106.63*
p-value < 0.0001
Note. The categories in ‘‘Excellent’’ and ‘‘Very good’’ were collapsed into 1 since only 3 responses were present in both. SF-1 consists of
a single question asking, ‘‘In general how would you rate your health?’’
a pre-BD spirometry.
* p < 0.05.
Figure 1 The lung function questionnaire. Copyright (c) 2008 GlaxoSmithKline. All rights reserved.
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1168 N.A. Hanania et al.dialogue that can aid in addressing patients’ respiratory
symptoms. There is potential for a screening tool to further
stratify likely cases with obstruction using a more severe
criterion measure (FEV1/FVC < 0.7 and % predicted
FEV1 < 65%, for example) and consequently a lower cut
point for the LFQ. These possibilities will be investigated
further in subsequent studies conducted using the LFQ.
When the criterion measure was redefined in the current
study to FEV1/FVC < 0.7 and % predicted FEV1 < 65%,
screening characteristics still indicated a negative predic-
tive value of 96% at a lower cut point of 14 (data not
shown). These results suggest that while targeting a more
severe group the LFQ may miss only 4% of possible cases
(majority of this 4% possibly milder) and thus affirms its
status as a case finding tool.
The screening accuracy of the LFQ was significantly
better with ordinal item-response scales than with binary
(yes/no) item-response scales. The screening accuracy of
the questionnaire was 78% with items having 5-point
response scales compared with 74% with items having yes/
no response scales. These findings are consistent with
previous evidence suggesting that continuum-based scales
have better psychometric properties than dichotomous
yes/no scales.22 The failure of the AL to add any value to
the LFQ was surprising based on clinical experience and
work on previous COPD and Asthma questionnaires.23,24
However the lack of concordance between reported dysp-
nea and activity limitation suggests that the questions for
these 2 areas are measuring different concepts. The hope
that an AL item could identify patients that considered
themselves asymptomatic due to modification of activities
was not realized. It was difficult to obtain consensus among
physicians and patients on the exact wording of the AL
question to make a question that was both sufficiently
general as well as specific. It appears that many patients
with COPD learn to cope with their impairment but do not
perceive those modifications as AL. The group agreed that
this question would be best asked within the context of
patient-physician introductory verbal dialog as opposed to
part of a questionnaire. Cough and dyspnea did not reach
statistical significance in the combined model. Both these
variables were strong independent predictors of airflow
obstruction within a bivariate model. Within a multivariate
regression framework, with independent variables
competing for variance in the dependent model, these
variables lost statistical significance (multicollinearity).
Excluding these variables from the model did not signifi-
cantly improve screening accuracy. Moreover, model
performance was not adversely impacted when cough and
dyspnea were retained. Also, in view of the face/clinical
validity of cough and dyspnea, these 2 important concepts
were retained in the final LFQ. Other studies of similar tools
have identified cough and dyspnea as being important
predictors of airflow obstruction as well.
LFQ demonstrated very good screening accuracy
regardless of whether airflow obstruction was defined as
FEV1/FVC < 0.70 or according to the more stringent crite-
rion of FEV1/FVC < 0.70 and FEV1 < 80% of predicted.
1 In
fact, the screening accuracy of the LFQ increased, as
reflected by an increase in the AUC, with the more strin-
gent criterion for definition of airflow obstruction. This
pattern of results suggests that the questionnaire is notvulnerable to misclassification of natural, age-related
diminishment in lung capacity as the presence of airflow
obstruction. A classification scheme relying on FEV1/FVC
alone potentially introduces a large false-positive rate
among elderly respondents who have age-related dimin-
ishment in lung capacity (‘‘aging’’ lung). Both the GOLD
guidelines and the ATS/ERS guidelines use a similar
spirometry-based diagnosis paradigm as well as similar
severity staging.1,15
The development phase of the LFQ has been described
elsewhere.16 In this study, body mass index (BMI) (specifi-
cally, BMI < 25) was also statistically significant in stepwise
analyses, it was only weakly related to pre-bronchodilator
FEV1/FVC in linear regression analyses. This variable was
eliminated from consideration for the reduced subset
because of low discriminatory power and the difficulty of
easily and reliably assessing it in a patient-reported ques-
tionnaire (as calculation involves computation). Smoking
was captured in terms of both number of cigarettes smoked
and duration of smoking in the validation study. Both of
these variables were highly collinear because they captured
related information. Smoking duration was used in the final
model based on the results of stepwise selection
procedures.
The objective of the LFQ is to include questions that are
easily completed by patients with information readily
known to them without any computations. Content of items
was both driven and confirmed by patients and physicians,
and question and response options were refined based on
patient and physician feedback in order to maximize their
relevance to patients and to the disease of interest.16 This
tool was part of a rigorous scientific process and guided by
a scientific committee comprising expert pulmonologists
and primary care physicians in academic settings. The LFQ
is unique among existing COPD screening/case finding
tools25e35 in having demonstrated both content validity and
face validity, which are critical to utility in clinical prac-
tice. A recent questionnaire, the COPD-PS, was developed
to explore similar objectives.26 The LFQ has several
advantages over the COPD-PS as well as other similarly
developed screening questionnaires. Feedback from both
patients and physicians (primary care as well as specialists)
drove the item development as well as validation process
for the LFQ. Patient feedback is important to developing
a patient-reported outcomes measure. LFQ incorporated
patient feedback at various stages in development as well
as validation process. Spirometry performed in the LFQ
validation study had a high degree of acceptance to
American Thoracic Society spirometric standards (very few
unusable/irreproducible spirometries) unlike the study
reported by Martinez et al.26 Also, in the development
sample for the COPD-PS, initial models constructed based
on usable spirometries (nZ 295) were applied to the entire
sample (n Z 697) to conduct psychometric analyses,
a practice that is not optimal.
Several characteristics render the LFQ particularly
appropriate for use in the busy primary care setting: the
LFQ is easy to self-administer, does not require interviewer
administration or information from medical records, and is
broadly useful across patient types. Other potential appli-
cations of the LFQ include use as an initial case finder in
epidemiological studies, disease management programs,
Validation of the LFQ 1169and clinical research. While the LFQ can help health care
providers identify patients in need of further evaluation for
possible COPD, it is not intended to be used as a diagnostic
tool. Patients whose LFQ score suggests the presence of
airflow obstruction require clinical evaluation and spiro-
metric testing to assess for and confirm diagnosis of COPD.
The results of this study should be interpreted with the
knowledge that pre-BD spirometry was used as the criterion
measure. Post-bronchodilator spirometry, after accounting
for reversibility, is generally regarded as a more accepted
measure of lung function than pre-BD spirometry. Also,
GOLD stages have been defined (albeit pre-BD) as sensi-
tivity analyses that show minimal changes to screening
accuracy and performance of individual questions. In
subsequent studies of the LFQ, post-bronchodilator
spirometry will be explored as a criterion measure. This
change is not expected to result in any major changes in the
characteristics or performance of questionnaire. Also, data
were collected from the state of Kentucky, which may not
be representative of the United States population.
However, the inclusion of both rural and urban locations
might render the data representative in this regard. The
degree to which the results generalize to countries other
than the United States is not known although the authors
are aware of no reason to suggest that the results would
differ in other countries. One limitation of the tool may be
asymptomatic older patients with a significant smoking
history may turn out to score 18 on LFQ and thus classified
as ‘‘at risk’’. For example, an aymptomatic 72-year old
with a 20 pack year history of smoking would score 18 on
the LFQ. While this person may not have symptoms, one
might argue that this is the patient who may need further
questioning as to whether they are minimizing symptoms.
By definition, they are at risk and this tool points out that
further workup may be necessary. Another limitation of this
case-finding tool is the potential of finding cases of
potential obstruction that are not confirmed by spirometry
(false positives). LFQ does have a higher rate of false
positives. With any patient reported tool, a good blend of
sensitivity and specificity aims to reach a fair balance in
that the tool doesn’t find too many false positives but at
the same time doesn’t miss too many cases (true positives).
Considering the high prevalence of undiagnosed COPD, the
LFQ WG felt that a cut point targeted to not miss too many
cases was needed for the LFQ. A factor to consider in
certain segments of primary care is also the cost of
spirometry which rules out its use as a population screener.
Therefore, the LFQ can serve as a conduit to reduce per-
forming spirometry in every symptomatic at risk patient
with a smoking history and result in conducting further
evaluation in smaller subset of patients with the knowledge
that the tool will not miss too many potential cases, a key
objective in COPD care. Of course, the LFQ false positive
rate is also associated with cost concerns but in the current
environment health plans and insurance companies do vest
heavily in disease management programs as well as
prevention (of exacerbations) initiatives for a chronic
progressive disease like COPD.
In summary, the LFQ is a simple, 5 item COPD case
finding tool with good screening accuracy in a primary care
patient population. This research extends previous findings
establishing the instrument’s content validity and facevalidity according to primary care physicians and
patients.16 The LFQ is an appropriate case finding tool to
facilitate early recognition and diagnosis of COPD in
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